UV-vis spectroscopy |
240–340 nm |
Cell density, aromatic amino acids |
– |
[48] |
Circular dichroism |
190–260 nm |
Proteins secondary structure, aggregation. |
– |
[49] |
FT-NIR spectroscopy |
750–2500 nm |
Chemical/biological compositions |
Brucker, USA |
[48] |
Raman spectroscopy |
100–3500 cm–1
|
antibody concentration |
Pfizer, USA; GlaxoSmithKline, USA |
[50] |
Fluorescence spectroscopy |
Excitation: 240–300 nm; emission: 260–450 nm |
Cell metabolism, fluorescent compounds in media. |
Sartorius Stedim Biotech GmbH, Germany |
[28] |
DLS |
Visible light |
Macromolecule diffusion |
Colloid Metrix GmbH, Germany; Sanofi-Aventis Deutschland GmbH, Germany |
[9] |
SLS |
Visible light |
Size of macromolecules in solution |
Sanofi-Aventis |
[9] |
Multiangle light scattering |
Visible light |
Protein aggregation |
Merck & Co., Inc., USA; Wyatt Technology Corporation, USA |
[51] |